期刊
MARINE DRUGS
卷 18, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/md18120619
关键词
marine natural products; marine drugs; anticancer; drug discovery; clinical pipeline
资金
- COST (European Cooperation in Science and Technology) programme [CA18238]
- Applied Molecular Biosciences Unit-UCIBIO - FCT/MCTES [UID/Multi/04378/2019]
- FCT/MCTES [IF/00700/2014]
- Slovenian Research Agency [P1-0245]
- TUB.ITAK grant [216Z167]
- Ministerio de Ciencia e Innovacion [RTA 2015-00010-C03-02]
- Agustin de Betancourt Programme (MEDI fund)
- Agustin de Betancourt Programme (FDCAN fund)
- MetaboCell project of Canceropole Provence-Alpes-Cote d'Azur
- Provence-Alpes-Cote d'Azur Region
- Marine Institute [PBA/MB/16/01, PDOC/19/02/01]
- Irish Government [PBA/MB/16/01, PDOC/19/02/01]
The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve different pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year. Marine-based pharmaceuticals have started to impact modern pharmacology and different anti-cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据